Thymalfasin: An immune system enhancer for the treatment of liver disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 19, Issue 12, 2004, Pages

  Sjogren, Maria H ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Chemical properties; Mechanism of action; Thymalfasin

Indexed keywords

IMMUNOMODULATING AGENT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; THYMOSIN ALPHA1; ANTIVIRUS AGENT; CYTOKINE; HLA ANTIGEN CLASS 1; IMMUNOLOGIC FACTOR; THYMOSIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; CELL MATURATION; COLORECTAL CARCINOMA; CONFERENCE PAPER; CYTOKINE PRODUCTION; DRUG DOSE REGIMEN; DRUG MECHANISM; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOPHARMACOLOGY; INFLUENZA; INHIBITION KINETICS; LIVER DISEASE; LYMPHOCYTE DIFFERENTIATION; MELANOMA; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TH1 CELL; VIRUS REPLICATION; AMINO ACID SEQUENCE; ANALOGS AND DERIVATIVES; ANIMAL; APOPTOSIS; CHEMISTRY; DRUG EFFECTS; IMMUNOLOGY; LIVER DISEASES; LYMPHOCYTE; LYMPHOPOIESIS; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; VIROLOGY;

AMINO ACID SEQUENCE; ANIMALS; ANTIVIRAL AGENTS; APOPTOSIS; CYTOKINES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOLOGIC FACTORS; LIVER DISEASES; LYMPHOCYTES; LYMPHOPOIESIS; MOLECULAR SEQUENCE DATA; THYMOSIN; VIRUS REPLICATION; ADJUVANTS, IMMUNOLOGIC; VIRUS DISEASES;

EID: 11144229462     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1400-1746.2004.03635.x     Document Type: Conference Paper

References (13)

1. Low TLK, Goldstein AL. Thymosins: structure, function, and therapeutic applications. Thymus 1984; 6: 27-42.
2. Rasi G, Pierimarchi P, Sinibaldi-Vallebona P, Colella F, Garaci E. Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma. Int. Immunopharmacol. 2003; 3: 1169-76.
3. Knutsen AP, Freeman JJ, Mueller KR, Roodman ST, Bouhasin JD. Thymosin-alpha1 stimulates maturation of CD34+ stem cells into CD3+4+ cells in an in vitro thymic epithelia organ coculture model. Int. Immunopharmacol. 1999; 21: 15-26.
4. Silecchia G, Guarino E, Sinibaldi-Vallebona P et al. Efficacy of repeated cycles of chemo-immunotherapy with thymosin alpha and interleukin-2 after intraperitoneal 5-fluorouracil delivery. Cancer Immunol. Immunother 1999; 48: 172-8.
5. Hadden JW, Saha A, Sosa M, Hadden EM. Immunotherapy with natural interleukins and/or thymosin alpha 1 potently augments T-lymphocyte responses of hydrocortisonetreated aged mice. Int. J. Immunopharmacol. 1995; 17: 821-8.
6. Kawarabayashi N, Seki S, Hatsuse K et al. Decrease of CD56 (+) T cells and natural killer cells in cirrhotic livers with hepatitis C may be involved in their susceptibility to hepatocellular carcinoma. Hepatology 2000; 32: 962-9.
7. Andreone P, Cursaro C, Gramenzi A et al. In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C. J. Viral Hepat 2001; 8: 194-201.
8. Roy R, Singh SM, Shanker A. Mechanism of thymocyte apoptosis induced by serum of tumor-bearing host: the molecular events involved and their inhibition by thymosin alpha-1. Int. J. Immunopharmacol. 2000; 22: 309-21.
9. Gupta S, Aggarwal S, Nguyen T. Accelerated spontaneous programmed cell death in lymphocytes in DiGeorge syndrome. J. Allergy Clin. Immunol. 1997; 99: S3 (No 11).
10. Giuliani C, Napolitano G, Mastino A et al. Thymosin a-1 regulates MHC class I expression in FRTL-5 cells at ranscriptional level. Eur J. Immunol. 2000; 30: 778-6.
11. Gerin JL, Korba BE, Cote PJ, Tennant BC. A preliminary report of a controlled study of thymosin alpha-1 in the woodchuck model of hepadnavirus infection. Adv. Exp. Mod. Biol. 1992; 312: 121-3.
12. Nakamura I, Nupp JT, Cowlen M et al. Pathogenesis of experimental neonatal woodchuck hepatitis virus infection. Chronicity as an outcome of infection is associated with a diminished acute hepatitis that is temporally deficient for the expression of interferon gamma and tumor necrosis factor-alpha messenger RNAs. Hepatology 2001; 33: 439-7.
13. Colledge D, Wang Y, Tuthill C, Locarnini S. Antiviral effects of thymosin alpha 1 versus leukocytic interferon in primary cultures of duck hepatocytes persistently infected with duck HBV in vitro. Paper presented at Second International Conference on Therapies for Viral Hepatitis. Kona, Hawaii, 1997.